{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:06:16Z","timestamp":1787666776140,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QB172"],"award-info":[{"award-number":["ZR2021QB172"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH141"],"award-info":[{"award-number":["ZR2021MH141"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH292"],"award-info":[{"award-number":["ZR2021MH292"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["2023CXPT012"],"award-info":[{"award-number":["2023CXPT012"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn201812100"],"award-info":[{"award-number":["tsqn201812100"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tstp20221145"],"award-info":[{"award-number":["tstp20221145"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31771284"],"award-info":[{"award-number":["31771284"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple tumors are synergistically promoted by c-Met and TRK, and blocking their cross-signalling pathway may give better effects. In this study, we developed a tyrosine kinase inhibitor 1D228, which exhibited excellent anti-tumor activity by targeting c-Met and TRK. Models in vitro, 1D228 showed a significant better inhibition on cancer cell proliferation and migration than the positive drug Tepotinib. Models in vivo, 1D228 showed robust anti-tumor effect on gastric and liver tumor growth with 94.8% and 93.4% of the TGI, respectively, comparing 67.61% and 63.9% of Tepotinib. Importantly, compared with the combination of Larotrectinib and Tepotinib, 1D228 monotherapy in MKN45 xenograft tumor models showed stronger antitumor activity and lower toxicity. Mechanistic studies showed that 1D228 can largely inhibit the phosphorylation of TRKB and c-Met. Interestingly, both kinases, TRKs and c-Met, have been found to be co-expressed at high levels in patients with gastric cancer through IHC. Furthermore, bioinformatics analysis has revealed that both genes are abnormally co-expressed in multiple types of cancer. Cell cycle analysis found that 1D228 induced G0\/G1 arrest by inhibiting cyclin D1. Additionally, vascular endothelial cells also showed a pronounced response to 1D228 due to its expression of TRKB and c-Met. 1D228 suppressed the migration and tube formation of endothelial cells, which are the key functions of tumor angiogenesis. Taken together, compound 1D228 may be a promising candidate for the next generation of c-Met and TRK inhibitors for cancer treatment, and offers a novel potential treatment strategy for cancer patients with abnormal expressions of c-Met or NTRK, or simultaneous of them.<\/jats:p>","DOI":"10.1038\/s41419-023-06246-5","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T14:02:02Z","timestamp":1699538522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A novel c-Met\/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation"],"prefix":"10.1038","volume":"14","author":[{"given":"Baijiao","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-645X","authenticated-orcid":false,"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"6246_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24367-3","volume":"12","author":"E Uchikawa","year":"2021","unstructured":"Uchikawa E, Chen Z, Xiao GY, Zhang X, Bai XC. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12:4074.","journal-title":"Nat Commun"},{"key":"6246_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-016-0366-y","volume":"9","author":"BQ Lam","year":"2016","unstructured":"Lam BQ, Dai L, Qin Z. The role of HGF\/c-MET signaling pathway in lymphoma. J Hematol Oncol. 2016;9:135.","journal-title":"J Hematol Oncol"},{"key":"6246_CR3","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.3390\/cancers13225738","volume":"13","author":"CH Kang","year":"2021","unstructured":"Kang CH, Kim Y, Lee DY, Choi SU, Lee HK, Park CH. c-Met-specific chimeric antigen receptor T cells demonstrate anti-tumor effect in c-Met positive gastric cancer. Cancers. 2021;13:5738.","journal-title":"Cancers"},{"key":"6246_CR4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.24796","volume":"55","author":"T Ishikawa","year":"2012","unstructured":"Ishikawa T, Factor VM, Marquardt JU, Raggi C, Seo D, Kitade M, et al. Hepatocyte growth factor\/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology. 2012;55:1215\u201326.","journal-title":"Hepatology"},{"key":"6246_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/annonc\/mds463","volume":"24","author":"GT Gibney","year":"2013","unstructured":"Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24:343\u20139.","journal-title":"Ann Oncol"},{"key":"6246_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/med.21885","volume":"42","author":"G Floresta","year":"2022","unstructured":"Floresta G, Abbate V. Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography. Med Res Rev. 2022;42:1588\u2013606.","journal-title":"Med Res Rev"},{"key":"6246_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/cac2.12124","volume":"41","author":"H Tanaka","year":"2021","unstructured":"Tanaka H, Taima K, Makiguchi T, Nakagawa J, Niioka T, Tasaka S. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation. Cancer Commun. 2021;41:83\u201387.","journal-title":"Cancer Commun"},{"key":"6246_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Tepotinib: First Approval. Drugs. 2020;80:829\u201333.","journal-title":"Drugs"},{"key":"6246_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2023;9:1260\u201366.","journal-title":"JAMA Oncol"},{"key":"6246_CR10","doi-asserted-by":"publisher","first-page":"eabn3231","DOI":"10.1126\/scitranslmed.abn3231","volume":"14","author":"C Swale","year":"2022","unstructured":"Swale C, Bellini V, Bowler MW, Flore N, Brenier-Pinchart MP, Cannella D, et al. Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase. Sci Transl Med. 2022;14:eabn3231.","journal-title":"Sci Transl Med"},{"key":"6246_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000515490","volume":"10","author":"F Finkelmeier","year":"2021","unstructured":"Finkelmeier F, Scheiner B, Leyh C, Best J, Fr\u00fcndt TW, Czauderna C, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-life cohort. Liver Cancer. 2021;10:360\u20139.","journal-title":"Liver Cancer"},{"key":"6246_CR12","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"H Jia","year":"2014","unstructured":"Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014;57:7577\u201389.","journal-title":"J Med Chem"},{"key":"6246_CR13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Savolitinib: first approval. Drugs. 2021;81:1665\u201370.","journal-title":"Drugs"},{"key":"6246_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, et al. Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol. 2021;16:1017\u201329.","journal-title":"J Thorac Oncol"},{"key":"6246_CR15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.bmcl.2015.02.002","volume":"25","author":"D Dorsch","year":"2015","unstructured":"Dorsch D, Schadt O, Stieber F, Meyring M, Gr\u00e4dler U, Bladt F, et al. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorg Med Chem Lett. 2015;25:1597\u2013602.","journal-title":"Bioorg Med Chem Lett"},{"key":"6246_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931\u201343.","journal-title":"N Engl J Med"},{"key":"6246_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04539-9","volume":"13","author":"JH Shi","year":"2022","unstructured":"Shi JH, Ling C, Wang TT, Zhang LN, Liu WW, Qin Y, et al. TRK-fused gene (TFG) regulates ULK1 stability via TRAF3-mediated ubiquitination and protects macrophages from LPS-induced pyroptosis. Cell Death Dis. 2022;13:93.","journal-title":"Cell Death Dis"},{"key":"6246_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.21037\/atm.2018.04.42","volume":"6","author":"A Anestis","year":"2018","unstructured":"Anestis A, Zoi I, Karamouzis MV. Current advances of targeting HGF\/c-Met pathway in gastric cancer. Ann Transl Med. 2018;6:247.","journal-title":"Ann Transl Med"},{"key":"6246_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2015.02.043","volume":"361","author":"NB Hao","year":"2015","unstructured":"Hao NB, Tang B, Wang GZ, Xie R, Hu CJ, Wang SM, et al. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K\/Akt\/NF-\u03baB signaling pathway for gastric cancer metastasis. Cancer Lett. 2015;361:57\u201366.","journal-title":"Cancer Lett"},{"key":"6246_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000484742","volume":"5","author":"A Valent","year":"1997","unstructured":"Valent A, Danglot G, Bernheim A. Mapping of the tyrosine kinase receptors trkA (NTRK1), trkB (NTRK2) and trkC (NTRK3) to human chromosomes 1q22, 9q22 and 15q25 by fluorescence in situ hybridization. Eur J Hum Genet. 1997;5:102\u20134.","journal-title":"Eur J Hum Genet"},{"key":"6246_CR21","doi-asserted-by":"crossref","unstructured":"Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol. 2018;2018:PO.18.00183.","DOI":"10.1200\/PO.18.00183"},{"key":"6246_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","volume":"8","author":"A Drilon","year":"2018","unstructured":"Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, et al. Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations. Cancer Discov. 2018;8:1227\u201336.","journal-title":"Cancer Discov"},{"key":"6246_CR23","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","volume":"26","author":"MR Yun","year":"2020","unstructured":"Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, et al. Repotrectinib exhibits potent antitumor activity in treatment-na\u00efve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. Clin Cancer Res. 2020;26:3287\u201395.","journal-title":"Clin Cancer Res"},{"key":"6246_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13046-019-1104-4","volume":"38","author":"T Luo","year":"2019","unstructured":"Luo T, Zhang SG, Zhu LF, Zhang FX, Li W, Zhao K, et al. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38:130.","journal-title":"J Exp Clin Cancer Res"},{"key":"6246_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/carcin\/bgi192","volume":"26","author":"M Hecht","year":"2005","unstructured":"Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L. The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. Carcinogenesis. 2005;26:2105\u201315.","journal-title":"Carcinogenesis"},{"key":"6246_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/jcb.20459","volume":"95","author":"A Cramer","year":"2005","unstructured":"Cramer A, Kleiner S, Westermann M, Meissner A, Lange A, Friedrich K. Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3. J Cell Biochem. 2005;95:805\u201316.","journal-title":"J Cell Biochem"},{"key":"6246_CR27","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1038\/sj.onc.1205622","volume":"21","author":"A Morotti","year":"2002","unstructured":"Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene. 2002;21:4885\u201393.","journal-title":"Oncogene"},{"key":"6246_CR28","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/0008-5472.CAN-17-3124","volume":"78","author":"I Olmez","year":"2018","unstructured":"Olmez I, Zhang Y, Manigat L, Benamar M, Brenneman B, Nakano I, et al. Combined c-Met\/Trk inhibition overcomes resistance to CDK4\/6 inhibitors in glioblastoma. Cancer Res. 2018;78:4360\u20139.","journal-title":"Cancer Res"},{"key":"6246_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s44211-022-00076-9","volume":"38","author":"LS Foteeva","year":"2022","unstructured":"Foteeva LS, Nosova YN, Nazarov AA, Keppler BK, Timerbaev AR. Versatile analytical methodology for evaluation of drug-like properties of potentially multi-targeting anticancer metallodrugs. Anal Sci. 2022;38:627\u201332.","journal-title":"Anal Sci"},{"key":"6246_CR30","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.bmcl.2017.04.079","volume":"27","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Tice CM, Singh SB. Conformational control in structure-based drug design. Bioorg Med Chem Lett. 2017;27:2825\u201337.","journal-title":"Bioorg Med Chem Lett"},{"key":"6246_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2174\/1570163816666190502101803","volume":"17","author":"K Gandhi","year":"2020","unstructured":"Gandhi K, Shah U, Patel S. Drug stereochemistry: a prodigy for pharmacology and drug development. Curr Drug Discov Technol. 2020;17:565\u201373.","journal-title":"Curr Drug Discov Technol"},{"key":"6246_CR32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1039\/D0SC03496G","volume":"12","author":"R Zhang","year":"2020","unstructured":"Zhang R, Zhong Y, Lu Z, Chen Y, Li G. Rapid chiral analysis based on liquid-phase cyclic chemiluminescence. Chem Sci. 2020;12:660\u20138.","journal-title":"Chem Sci"},{"key":"6246_CR33","doi-asserted-by":"publisher","first-page":"106653","DOI":"10.1016\/j.bioorg.2023.106653","volume":"138","author":"B An","year":"2023","unstructured":"An B, Fan Y, Li W, Nie W, Nie H, Wang M, et al. Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer. Bioorg Chem. 2023;138:106653.","journal-title":"Bioorg Chem"},{"key":"6246_CR34","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.3390\/cancers14143444","volume":"14","author":"SH Sohn","year":"2022","unstructured":"Sohn SH, Sul HJ, Kim BJ, Zang DY. Responses to the Tepotinib in gastric cancers with MET amplification or MET Exon 14 skipping mutations and high expression of both PD-L1 and CD44. Cancers. 2022;14:3444.","journal-title":"Cancers"},{"key":"6246_CR35","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1158\/1078-0432.CCR-18-1156","volume":"24","author":"ES Kheder","year":"2018","unstructured":"Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24:5807\u201314.","journal-title":"Clin Cancer Res"},{"key":"6246_CR36","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.1021\/acs.jmedchem.6b00850","volume":"59","author":"SE Skerratt","year":"2016","unstructured":"Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, et al. The discovery of a potent, selective, and peripherally restricted Pan-Trk inhibitor (PF-06273340) for the treatment of pain. J Med Chem. 2016;59:10084\u201399.","journal-title":"J Med Chem"},{"key":"6246_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jmb.2012.08.002","volume":"423","author":"T Bertrand","year":"2012","unstructured":"Bertrand T, Kothe M, Liu J, Dupuy A, Rak A, Berne PF, et al. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol. 2012;423:439\u201353.","journal-title":"J Mol Biol"},{"key":"6246_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1021\/ml200261d","volume":"3","author":"P Albaugh","year":"2012","unstructured":"Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, et al. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett. 2012;3:140\u20135.","journal-title":"ACS Med Chem Lett"},{"key":"6246_CR39","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cells9122648","volume":"9","author":"FI Montalto","year":"2020","unstructured":"Montalto FI, De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells. 2020;9:2648.","journal-title":"Cells"},{"key":"6246_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03424-1","volume":"12","author":"A Xu","year":"2021","unstructured":"Xu A, Wang X, Luo J, Zhou M, Yi R, Huang T, et al. Overexpressed P75CUX1 promotes EMT in glioma infiltration by activating \u03b2-catenin. Cell Death Dis. 2021;12:157.","journal-title":"Cell Death Dis"},{"key":"6246_CR41","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.trecan.2019.05.007","volume":"5","author":"Y Fan","year":"2019","unstructured":"Fan Y. Vascular detransformation for cancer therapy. Trends Cancer. 2019;5:460\u20133.","journal-title":"Trends Cancer"},{"key":"6246_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jtbi.2017.11.025","volume":"439","author":"A Konstorum","year":"2018","unstructured":"Konstorum A, Lowengrub JS. Activation of the HGF\/c-Met axis in the tumor microenvironment: a multispecies model. J Theor Biol. 2018;439:86\u201399.","journal-title":"J Theor Biol"},{"key":"6246_CR43","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1158\/0008-5472.CAN-10-2186","volume":"71","author":"E Avilla","year":"2011","unstructured":"Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, et al. Activation of TYRO3\/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res. 2011;71:1792\u2013804.","journal-title":"Cancer Res"},{"key":"6246_CR44","unstructured":"Oliveros JC (2007\u20132015) Venny. An interactive tool for comparing lists with Venn\u2019s diagrams. https:\/\/bioinfogp.cnb.csic.es\/tools\/venny\/index.html."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06246-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T15:02:07Z","timestamp":1699542127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06246-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["6246"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06246-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2838957\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Human Research Ethics Committee of Binzhou Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"728"}}